Style | Citing Format |
---|---|
MLA | Taki E, et al.. "Cabotegravir/Rilpivirine: The Last Fda-Approved Drug to Treat Hiv." Expert Review of Anti-Infective Therapy, vol. 20, no. 8, 2022, pp. 1135-1147. |
APA | Taki E, Soleimani F, Asadi A, Ghahramanpour H, Namvar A, Heidary M (2022). Cabotegravir/Rilpivirine: The Last Fda-Approved Drug to Treat Hiv. Expert Review of Anti-Infective Therapy, 20(8), 1135-1147. |
Chicago | Taki E, Soleimani F, Asadi A, Ghahramanpour H, Namvar A, Heidary M. "Cabotegravir/Rilpivirine: The Last Fda-Approved Drug to Treat Hiv." Expert Review of Anti-Infective Therapy 20, no. 8 (2022): 1135-1147. |
Harvard | Taki E et al. (2022) 'Cabotegravir/Rilpivirine: The Last Fda-Approved Drug to Treat Hiv', Expert Review of Anti-Infective Therapy, 20(8), pp. 1135-1147. |
Vancouver | Taki E, Soleimani F, Asadi A, Ghahramanpour H, Namvar A, Heidary M. Cabotegravir/Rilpivirine: The Last Fda-Approved Drug to Treat Hiv. Expert Review of Anti-Infective Therapy. 2022;20(8):1135-1147. |
BibTex | @article{ author = {Taki E and Soleimani F and Asadi A and Ghahramanpour H and Namvar A and Heidary M}, title = {Cabotegravir/Rilpivirine: The Last Fda-Approved Drug to Treat Hiv}, journal = {Expert Review of Anti-Infective Therapy}, volume = {20}, number = {8}, pages = {1135-1147}, year = {2022} } |
RIS | TY - JOUR AU - Taki E AU - Soleimani F AU - Asadi A AU - Ghahramanpour H AU - Namvar A AU - Heidary M TI - Cabotegravir/Rilpivirine: The Last Fda-Approved Drug to Treat Hiv JO - Expert Review of Anti-Infective Therapy VL - 20 IS - 8 SP - 1135 EP - 1147 PY - 2022 ER - |